Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma without ID3-TCF3-CCND3 pathway deregulation

ABSTRACT: Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma without ID3-TCF3-CCND3 pathway deregulation

PROVIDER: PRJNA478946 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma without ID3-TCF3-CCND3 pathway deregulation [ONCOSCAN]

Project description:Burkitt-like lymphoma with 11q aberration (BLL-11q) is a new provisional category in the 2016 WHO classification. The limited number of reported cases does not allow to define whether this is a specific entity or it is a particular variant of other recognized categories such as Burkitt or diffuse large B-cell lymphoma. The genetic alterations involved in the pathogenesis of BLL-11Q are not known.

2019-02-19 | GSE116526 | GEO

Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma without ID3-TCF3-CCND3 pathway deregulation [CYTOSCAN]

2019-02-19 | GSE116522 | GEO

Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma without ID3-TCF3-CCND3 pathway deregulation [SNP6]

2019-02-19 | GSE116518 | GEO

Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma without ID3-TCF3-CCND3 pathway deregulation [ONCOSCAN]

Project description:Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma without ID3-TCF3-CCND3 pathway deregulation [ONCOSCAN]

| PRJNA478933 | ENA

Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma without ID3-TCF3-CCND3 pathway deregulation [CYTOSCAN]

Project description:Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma without ID3-TCF3-CCND3 pathway deregulation [CYTOSCAN]

| PRJNA478928 | ENA

Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma without ID3-TCF3-CCND3 pathway deregulation [SNP6]

Project description:Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma without ID3-TCF3-CCND3 pathway deregulation [SNP6]

| PRJNA478920 | ENA

Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma without ID3-TCF3-CCND3 pathway deregulation

Project description:This SuperSeries is composed of the SubSeries listed below.

2019-02-19 | GSE116527 | GEO

Burkitt-like lymphoma with 11q aberration

Project description:Morphological and genetic study of Burkitt-like lymphoma with 11q aberration

| PRJEB27947 | ENA

Comprehensive immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration by flow-cytometry

Project description:Recently, a subset of MYC-translocation negative aggressive B-cell lymphomas resembling Burkitt lymphoma (BL) characterized by proximal gains and distal losses in the long arm of chromosome 11 has been described. In the 2016 revision of the WHO classification these MYC-translocation negative lymphomas have been introduced as new provisional entity designated “Burkitt-like lymphoma with 11q aberration” (MNBLL 11q). Here, we show a comprehensive flow-cytometry analysis of 10 MNBLL 11q cases, well characterized genetically and pathologically. Twenty-three cases of MYC-positive BL, including three cases carrying both MYC rearrangements and 11q aberration, served as controls. All MNBLL 11q were CD20+/CD10+/BCL6+/BCL2- /MUM1- /MYC+/EBV negative , presented a high proliferation rate and showed a three-year overall survival (80%) similar to BL patients, with no recurrence after the end of treatment. MNBLL 11q immunophenotype was similar to that of MYC-positive BL without and with 11q, except for less frequent CD38higher expression (10% MNBLL 11q vs 91% MYC-positive BL, p<0.001), less frequent diminished CD45 expression (90% vs 23%, p=0.001), and CD16/CD56 co-expression (60% vs 0%, p<0.001). Our findings suggest subtle but important differences in MNBLL 11q immunophenotypes and MYC-positive BLs, which could not only aid in the differential diagnosis but also in the understanding of the pathogenesis of MNBLL 11q.

2019-07-30 | GSE93002 | GEO

The 11q-gain/loss aberration occurs recurrently in MYC-negative as well as MYC-positive Burkitt lymphoma and high grade B cell lymphoma

Project description:Detailed analysis of 11q aberrations consisted of duplication, terminal deletion and inversion performed by SNP/aCGH on 11 patients with BLL,11q; BL and HGBL,NOS diagnosis.

2017-05-02 | GSE98371 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data